Cyclic hydroxylamine as psychoactive compounds

Details for Australian Patent Application No. 2004247462 (hide)

Owner BTG International Limited

Inventors Rosini, Sergio; Parsons, Philip; Annis, Michael; Trasciatti, Silvia

Agent Watermark

Pub. Number AU-B-2004247462

PCT Pub. Number WO2004/111021

Priority 0313628.0 12.06.03 GB; 0328439.5 08.12.03 GB

Filing date 1 June 2004

Wipo publication date 23 December 2004

Acceptance publication date 2 September 2010

International Classifications

A61P 25/22 (2006.01) Drugs for disorders of the nervous system

A61K 31/445 (2006.01) - Non-condensed piperidines, e.g. piperocaine

A61K 31/451 (2006.01) - having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine

A61K 31/5375 (2006.01) - 1,4-Oxazines, e.g. morpholine

A61P 25/24 (2006.01) Drugs for disorders of the nervous system

C07D 211/94 (2006.01) Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings

C07D 265/30 (2006.01) Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms

Event Publications

5 January 2006 PCT application entered the National Phase

  PCT publication WO2004/111021 Priority application(s): WO2004/111021

2 September 2010 Application Accepted

  Published as AU-B-2004247462

6 January 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004247468-2-hydroxymethyl-3,4,5-trihydroxy-1-(4-p entlyoxybenzyl) piperidine as glucosylceramide synthase (GCS)

2004247457-Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5b of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use